Donepezil (Aricept) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Donepezil (brand name Aricept) is a centrally-acting, reversible acetylcholinesterase (AChE) inhibitor and the most widely prescribed medication for Alzheimer's disease. Developed by Eisai and co-marketed with Pfizer, donepezil was first approved by the FDA in 1996 and provides symptomatic relief by increasing acetylcholine levels in [@birks2018]
the brain, compensating for the progressive loss of cholinergic neurons — particularly in the nucleus basalis of Meynert — that characterizes Alzheimer's pathology.[@rogers1998] [@noetzli2013]
Donepezil is approved for the treatment of mild, moderate, and severe Alzheimer's Disease. While it does not modify the underlying disease process or halt neurodegeneration, it remains a first-line pharmacotherapy that can temporarily stabilize or modestly improve cognitive function, daily activities, and behavioral symptoms. It is one of three cholinesterase inhibitors approved for AD, alongside galantamine and rivastigmine.[@birks2018] Donepezil became available as a generic medication in November 2010 following patent expiration, and is now manufactured by numerous generic pharmaceutical companies worldwide. [@kim2017]
Donepezil's mechanism is rooted in the cholinergic hypothesis of Alzheimer's Disease, which posits that degeneration of cholinergic neurons in the basal forebrain — particularly the nucleus basalis of Meynert — leads to a deficit of acetylcholine (ACh) in cortical and hippocampal regions, contributing to the cognitive symptoms of AD. The cholinergic deficit correlates with disease severity: mild AD patients show approximately 50% reduction in cortical choline acetyltransferase (ChAT) activity, increasing to >90% reduction in severe disease. [@zhang2024]
Donepezil binds reversibly and non-competitively to acetylcholinesterase (AChE), the enzyme responsible for hydrolyzing ACh in synaptic clefts. Key pharmacological properties: [@zhao2024]
- High AChE selectivity: Donepezil is approximately 1,000-fold more selective for AChE over butyrylcholinesterase (BuChE), distinguishing it from rivastigmine, which inhibits both enzymes. This selectivity is clinically significant because BuChE activity increases in AD brains while AChE decreases
- Central selectivity: Preferentially inhibits brain AChE over peripheral AChE, reducing gastrointestinal side effects compared to physostigmine and tacrine
- Long half-life: Elimination half-life of approximately 70 hours, enabling convenient once-daily dosing and maintaining stable plasma levels at steady state[@noetzli2013]
- Reversible binding: Binds to both the catalytic active site (CAS) and peripheral anionic site (PAS) of AChE, with particularly high affinity for the PAS — which is also the site where amyloid-beta interacts with AChE, potentially conferring additional anti-amyloid properties
- AChE inhibition: At therapeutic doses, donepezil inhibits approximately 25–40% of brain AChE activity, as measured by PET studies using 11Cdonepezil
By inhibiting AChE, donepezil increases the concentration and duration of action of ACh at cholinergic synapses throughout the cerebral cortex and hippocampus, supporting cholinergic neurotransmission that underlies attention, memory, and learning. [@farlow2010]
Emerging research suggests donepezil may have additional neuroprotective and disease-modifying effects beyond cholinergic enhancement: [@howard2012]
- Anti-inflammatory effects: Modulation of microglial[@kim2017]
- Anti-amyloid effects: Reduction of amyloid-beta production and aggregation in preclinical models, potentially through upregulation of the non-amyloidogenic α
- Anti-excitotoxic effects: Protection against glutamate excitotoxicity via modulation of NMDA receptor activity
- Nicotinic receptor upregulation: Chronic donepezil treatment upregulates nicotinic acetylcholine receptors (nAChRs), particularly α4β2 and α7 subtypes, which are important for synaptic plasticity and neuroprotection[@kim2017]
- Cerebrovascular effects: Improvement of cerebral blood flow, potentially through nitric oxide-mediated vasodilation and reduced blood-brain barrier dysfunction
A 2024 systematic review and meta-analysis found that AChE inhibitors — particularly donepezil at 10 mg — significantly reduce the rate of hippocampal atrophy in both AD and mild cognitive impairment (MCI) patients compared to placebo. This structural preservation suggests a potential neuroprotective effect beyond purely symptomatic cholinergic enhancement, though the mechanism remains under investigation.[@zhang2024] [@park2024]
In randomized controlled trials, donepezil at 5 mg and 10 mg daily demonstrated: [@cacabelos2007]
- ADAS-Cog improvement: 2.5–3.1 point improvement over placebo at 24 weeks (clinically meaningful threshold is typically 4 points)[@rogers1998]
- CIBIC-plus: Statistically significant improvement in global clinical impression
- MMSE: Modest improvement of 1.0–1.8 points over placebo at 24 weeks
- Activities of Daily Living (ADL): Significant preservation of functional abilities
A 2018 Cochrane meta-analysis encompassing 30 trials confirmed these findings, concluding that donepezil produces modest but consistent benefits on cognitive function, activities of daily living, and clinician-rated global clinical state in mild to moderate AD.[@birks2018] [@sugimoto1995]
A 2024 systematic review and meta-analysis comparing 5 mg and 10 mg doses found that donepezil 10 mg/day is more efficacious than 5 mg/day for improving cognitive function, supporting dose-dependent therapeutic effects.[@zhao2024] [@arai2018]
Donepezil 10 mg and 23 mg formulations have shown:
- Modest cognitive benefits on the Severe Impairment Battery (SIB)
- Functional improvement on the ADCS-ADL-severe scale
- The 23 mg dose provides greater cognitive benefit than 10 mg but with more gastrointestinal side effects[@farlow2010]
- Benefits are typically observed within 3–6 months of initiation
- The symptomatic effect diminishes as the disease progresses and cholinergic neurons are further lost
- Discontinuation often leads to rapid decline to a level comparable to untreated patients
- Some patients show benefit for 2–3 years; the drug does not halt disease progression
- The DOMINO-AD trial showed that discontinuing donepezil in moderate-to-severe AD led to significantly worse cognitive and functional outcomes compared to continuation, supporting continued use even in later disease stages[@howard2012]
Real-world studies have generally confirmed trial findings, with some caveats:
- Adherence rates decline over time, with only ~50–60% of patients continuing treatment at 1 year
- Common reasons for discontinuation include perceived lack of efficacy, gastrointestinal side effects, and caregiver burden
- Patients who respond well in the first 3 months are more likely to show sustained benefit
- Long-term observational studies suggest donepezil users may have slower rates of nursing home placement compared to non-users
| Parameter |
Value |
| Bioavailability |
~100% (oral) |
| Time to peak (Tmax) |
3–4 hours |
| Half-life |
~70 hours |
| Protein binding |
~96% (albumin) |
| Metabolism |
CYP2D6, CYP3A4, glucuronidation |
| Excretion |
Renal (57%) and fecal (15%); unchanged drug ~17% in urine |
| Steady state |
~15 days |
The long half-life (70 hours) is a distinguishing feature of donepezil, permitting once-daily dosing and providing stable cholinesterase inhibition throughout the day. This contrasts with rivastigmine (half-life ~1.5 hours for oral, ~3 hours for patch) and galantamine (half-life ~7 hours), which require twice-daily or extended-release formulations.
Donepezil is primarily metabolized by CYP2D6 and CYP3A4 in the liver. Genetic polymorphisms in CYP2D6 affect drug metabolism:
- Poor metabolizers (PM): Show ~31.5% slower clearance and higher plasma levels
- Ultra-rapid metabolizers (UM): Show ~24% faster clearance and potentially subtherapeutic levels
- Extensive metabolizers (EM): Standard pharmacokinetic profile
A 2024 Korean study found that while donepezil plasma concentrations differed significantly among CYP2D6 metabolizer phenotypes, these differences did not significantly affect
3-year cognitive outcomes (MMSE) or adverse event rates, suggesting that routine CYP2D6 genotyping may not be necessary for donepezil dosing.[@park2024] However, other studies have
reported that specific genotypes (e.g., CYP2D6 G/G) are associated with higher response rates, and the clinical utility of pharmacogenomic testing remains an active area of
investigation.[@cacabelos2007]
¶ Dosing and Administration
| Formulation |
Dose |
Frequency |
Notes |
| Oral tablet |
5 mg, 10 mg, 23 mg |
Once daily (typically at bedtime) |
Start at 5 mg; increase to 10 mg after 4–6 weeks |
| Orally disintegrating tablet |
5 mg, 10 mg |
Once daily |
Dissolves on the tongue without water; useful for patients with swallowing difficulty |
| Transdermal patch |
5 mg/day, 10 mg/day |
Once daily |
May reduce GI side effects by avoiding first-pass metabolism |
Titration: Start at 5 mg daily for at least 4–6 weeks before increasing to 10 mg. The 23 mg dose (for moderate-to-severe AD) should only be initiated after at least 3 months on 10 mg daily. Dose adjustments are not required for renal or hepatic impairment, though caution is advised in severe hepatic disease.
Administration: Donepezil can be taken with or without food. Bedtime administration is often preferred to minimize awareness of cholinergic side effects (vivid dreams, insomnia may require morning dosing).
- Gastrointestinal: Nausea (11%), diarrhea (10%), vomiting (5%) — dose-related; more common at higher doses and during titration. GI effects are the most common reason for discontinuation
- Neurological: Insomnia (9%), dizziness (5%), abnormal dreams, headache
- Musculoskeletal: Muscle cramps (6%), particularly in the calves and feet
- Cardiovascular: Bradycardia, syncope (especially in patients on beta-blockers or with sick sinus syndrome)
- Other: Fatigue, anorexia, weight loss
- Cardiac: QT prolongation, bradycardia, heart block (rare); the vagotonic effect of increased ACh can slow heart rate. ECG monitoring is recommended in patients with cardiac conduction abnormalities
- GI: Peptic ulcer disease exacerbation, GI bleeding (rare) — ACh stimulates gastric acid secretion
- Seizures: Very rare; ACh excess can lower seizure threshold
- Rhabdomyolysis: Very rare; reported in association with neuroleptic malignant syndrome
- Hepatotoxicity: Very rare; unlike its predecessor tacrine, donepezil has an excellent hepatic safety profile
- CYP2D6 and CYP3A4 inhibitors (ketoconazole, fluoxetine, paroxetine): May increase donepezil levels; monitor for cholinergic side effects
- CYP3A4 inducers (rifampin, phenytoin, carbamazepine): May decrease donepezil levels, potentially reducing efficacy
- Anticholinergic medications (oxybutynin, diphenhydramine, tricyclic antidepressants): Directly counteract donepezil's mechanism — concomitant use is a common and avoidable cause of treatment failure
- Succinylcholine-type muscle relaxants: Enhanced and prolonged effect due to AChE inhibition; important to communicate to anesthesiologists before surgery
- NSAIDs: Increased GI bleeding risk due to combined effects on gastric mucosa
- Beta-blockers and calcium channel blockers: Additive bradycardic effects
The most common combination for moderate-to-severe AD. Memantine, an NMDA receptor receptor] antagonist, acts through a complementary mechanism by reducing glutamate-mediated excitotoxicity. The fixed-dose combination product Namzaric (donepezil 10 mg + memantine ER 28 mg) simplifies dosing. The DOMINO-AD trial showed that the combination provided additional benefit over either drug alone in moderate-to-severe AD.[@howard2012]
With the FDA approval of lecanemab (2023) and donanemab (2024), a new treatment paradigm has emerged combining symptomatic therapy (donepezil) with disease-modifying anti-amyloid therapy. Patients in the pivotal trials of these antibodies typically continued cholinesterase inhibitors, and current clinical practice recommends maintaining donepezil alongside anti-amyloid therapy. The rationale is complementary: donepezil boosts residual cholinergic signaling while anti-amyloid antibodies reduce amyloid-beta plaque burden to slow disease progression.
Donepezil is most effective as part of a comprehensive AD management plan that includes:
- Cognitive stimulation therapy
- Physical exercise programs
- Caregiver education and support
- Management of cardiovascular risk factors
- Treatment of comorbid depression and sleep disorders
| Feature |
Donepezil |
Rivastigmine |
Galantamine |
| AChE selectivity |
AChE >> BuChE |
AChE + BuChE |
AChE > BuChE |
| Mechanism |
Non-competitive |
Pseudo-irreversible |
Competitive + allosteric nAChR modulation |
| Half-life |
~70 hours |
~1.5 hours (oral) |
~7 hours |
| Dosing |
Once daily |
Twice daily (oral) or once daily (patch) |
Twice daily (IR) or once daily (ER) |
| Indications |
Mild-moderate-severe AD |
Mild-moderate AD, PD dementia |
Mild-moderate AD |
| Unique features |
Longest half-life, best tolerated |
Only one approved for PD dementia |
nAChR allosteric potentiation |
Head-to-head comparisons generally show similar efficacy among the three agents, with differences primarily in tolerability and dosing convenience. Donepezil's once-daily dosing and long half-life make it the most commonly prescribed first-line agent.
Donepezil has been investigated for several off-label indications, with varying levels of evidence:
- Vascular Dementia: Modest cognitive benefits in controlled trials
- Lewy body dementia: Some evidence for cognitive and behavioral improvement; may be better tolerated than antipsychotics
- Parkinson's disease dementia: Positive trial data, though rivastigmine is the approved agent
- Down syndrome-associated dementia: Limited evidence of benefit
- Traumatic brain injury: Investigated for cognitive rehabilitation
- Multiple sclerosis-related cognitive impairment: Inconsistent results
The study of Donepezil (Aricept) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
flowchart TD
A["Cholinergic Neuron Loss (Nucleus Basalis)"] --> B["Reduced ACh in Synapse"]
B --> C["Cognitive Decline"]
D["Donepezil"] --> E["AChE Inhibition"]
E --> F["Increased Synaptic ACh"]
F --> G["Muscarinic Receptor Activation"]
F --> H["Nicotinic Receptor Activation"]
G --> I["Improved Memory / Attention"]
H --> J["Synaptic Plasticity"]
D --> K["nAChR Upregulation"]
K --> J
D --> L["Anti-inflammatory Effects"]
L --> M["Reduced Microglial Activation"]
J --> N["Cognitive Stabilization"]
I --> N
| Property |
Value |
| Bioavailability |
100% |
| Half-life |
70 hours |
| Cmax |
4-8 hours |
| Protein binding |
96% |
| Metabolism |
CYP2D6, CYP3A4 |
| Excretion |
Renal |
| Measure |
Improvement |
| ADAS-Cog |
2-3 points |
| MMSE |
0.5-1 point |
| ADL |
Clinically meaningful |
| Global |
Stable for 12+ months |
- [Unknown, Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer's Disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med. 1998;158(9):1021-1031. . DOI (1998)
- [Unknown, Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's Disease. Cochrane Database Syst Rev. 2018;6(6):CD001190. . DOI (2018)
- [Unknown, Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's Disease. Clin Pharmacokinet. 2013;52(4):225-241. . DOI (2013)
- [Kim SH, Kandiah N, Hsu JL, et al., Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's Disease. Br J Pharmacol. 2017;174(23):4224-4232. . DOI (2017)
- [Zhang J, et al., Efficacy of acetylcholinesterase inhibitors on reducing hippocampal atrophy rate: a systematic review and meta-analysis. BMC Neurol. 2024;24:440. . DOI (2024)
- [Zhao L, et al., Efficacy of 5 and 10 mg donepezil in improving cognitive function in patients with dementia: a systematic review and meta-analysis. Front Neurosci. 2024;18:1398952. . DOI (2024)
- [Farlow MR, Salloway S, Tariot PN, et al, Effectiveness and tolerability of high-dose (23 mg/d] versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's Disease (2010)]([DOI:10.1016/j.clinthera.2010.06.019)(https://doi.org/10.1016/j.clinthera.2010.06.019))
- [Howard R, McShane R, Lindesay J, et al., Donepezil and memantine for moderate-to-severe Alzheimer's Disease. N Engl J Med. 2012;366(10):893-903. . DOI (2012)
- [Park SH, et al., The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's Disease. Pharmacogenomics J. 2024. PubMed (2024)
- Unknown, Cacabelos R. Donepezil in Alzheimer's Disease: from conventional trials to pharmacogenetics. Neuropsychiatr Dis Treat. 2007;3(3):303-333. [PMC (2007)
- [Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K, Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl]methyl]piperidine hydrochloride and related compounds (1995)]([DOI:10.1021/jm00024a009)(https://doi.org/10.1021/jm00024a009))
- [Arai H, Hashimoto N, Sumitomo K, et al, Disease state changes and safety of long-term donepezil hydrochloride administration in patients with Alzheimer's Disease (2018))